News

CIP at the 16th CIMT Annual Meeting

“Pushing Frontiers in Cancer Immunotherapy”

May 15-17, 2018 - Mainz

Please join us on Thursday, May 17, at 08:30 – 10:00, for the “Immunoguiding” plenary session. Reknown experts in their field will present their last data.

CIP will also be present at the Short Talk Session "Immunomonitoring" which will take place on the same day at 10:30 – 13:00. Posters selected for oral presentation as well as a summary of the CIP activities 2017-2018 will be presented. CIP sponsorizes the price for the best poster in this category.

For more information on the meeting, visit www.meeting.cimt.eu.

 

MDSCs Harmonization - Second phase

Results of the phase I proficiency panel have been published (S. Mandruzzato, PMID: 26728481).

Testing phase II (in silico) is completed and central analysis is ongoing. Contact: susanna.mandruzzato@unipd.it

 

Natural Killer Harmonization - Second phase

The second testing phase has been completed and results are available. Contact: Ruth.Challis@uhs.nhs.uk

 

Proficiency panel collaboration

The proficiency panel programs established by CIP and CIC have reached a high degree of harmonization for two immune monitoring methods, the HLA-multimer staining and Interferon-gamma ELISPOT. Starting in Fall 2013, the company Immudex has taken on the organization of large-scale proficiency panels for these two assays.

For general information about the Immudex proficiency panels as well as upcoming panels, please go to the Immudex website.

Resulst of the last Elispot panel are pending

T cell reference samples

Reference samples containing a controlled number of antigen-specific T cells that can be used for controlling assay performance overtime are urgently needed. In collaboration with the University Medical Clinic in Mainz and TRON, CIP has developed a RNA-based scalable technology which allows the generation of TCR-engineered reference samples (TERS) of selected specificities (Bidmon et al. doi: 10.4049). TERS can be used for controlling the performance of HLA-multimer, Elispot and ICS assays over time. TERS can be easily produced in-house using a kit-based approach. Since November 2016, TERS-kits have been proposed by the company jpt

About CIP

The CIMT Immunoguiding Program (CIP) is a working group founded in February 2005 under the aegis of the Association for Cancer Immunotherapy (CIMT).

The CIP activities are managed by a group of 8 members:

Marij J.P. Welters, PhD
Chair 2018


CIP Mission:
CIP's aim is to help establish high-quality immunomonitoring across the field. For this purpose, CIP supports the concept of immune monitoring harmonization and promotes the technical validation of in-vitro assays.

CIP Objective: to guide the development of innovative cancer immunotherapeutics on the basis of immunological outcomes.

CIP organizes proficiency panels to reach quality control and inter-laboratory harmonization of commonly applied immunomonitoring assays and to test new tools or assays which are of interest to the field. CIP covers educational aspects by organizing scientific sessions at the CIMT Annual Meeting and by proposing workshops. CIP guidelines are available on its homepage, and new insights are published in peer-review journals. So far, almost 80 laboratories from Europe and the USA have participated in CIP activities, and a number of labs have expressed their interest in joining upcoming panels. CIP cooperates with partner groups and institutions that share similar aims.

CIP receives support from the Wallace Coulter Foundation (Miami, Florida, USA) and industry partners.

The aims of the CIP working group are to:

establish a group of professional developers and users to exchange techniques, protocols and reagents, and to critically discuss immune monitoring issues.

organize interlaboratory testing projects in order to compare techniques, variables and local protocols used for measuring antigen-specific T cells and other immune cells.

propose technical guidelines and increase transparency for reporting results of in vitro assays (MIATA project).

advise in the monitoring of T-cell responses in clinical studies, including help for training staff members.

share experience with other scientists and working groups that are active in the field of immune monitoring.

promote immune monitoring and communicate significant developments in the field: CIP organizes scientific sessions during the CIMT Annual Meetings, and international speakers present their most recent results at the plenary immunoguiding session. CIP members meet once a year during the CIMT Meeting (CIP breakout session) in order to discuss ongoing CIP panels and results, learn more about new developments in the field, and address priorities for upcoming activities. The group is open to all laboratories that focus on the monitoring of immune cells.